NCT03640949

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest - A Randomized, Double-Blind, Placebo-Controlled Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 501 (actual)
• Sponsor: Lars Wiuff Andersen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

Conditions

• Heart Arrest

Interventions

Type	Name	Description
DRUG	Vasopressin, Arginine	20 IE of vasopressin per dose for a maximum of four doses (80 IU)
DRUG	Methylprednisolone	40 mg methylprednisolone once
DRUG	NaCl	Placebo

Timeline

• Start date: 2018-09-17
• Primary completion: 2021-01-21
• Completion: 2022-01-21
• First posted: 2018-08-21
• Last updated: 2022-03-02
• Results posted: 2022-01-11

Locations

10 sites across 1 country: Denmark